Compare HIW & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIW | VERA |
|---|---|---|
| Founded | 1978 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 1995 | 2021 |
| Metric | HIW | VERA |
|---|---|---|
| Price | $21.61 | $38.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $29.50 | ★ $80.56 |
| AVG Volume (30 Days) | ★ 1.6M | 886.2K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 9.03% | N/A |
| EPS Growth | ★ 54.26 | N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $806,112,000.00 | N/A |
| Revenue This Year | $6.91 | N/A |
| Revenue Next Year | $3.49 | $445.28 |
| P/E Ratio | $15.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.56 | $18.53 |
| 52 Week High | $32.76 | $56.05 |
| Indicator | HIW | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 31.87 | 34.71 |
| Support Level | $21.56 | $19.84 |
| Resistance Level | $23.68 | $56.05 |
| Average True Range (ATR) | 0.67 | 1.70 |
| MACD | -0.02 | -0.24 |
| Stochastic Oscillator | 16.19 | 11.06 |
Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.